Ntrk Gene Fusion-positive Solid Tumors

• FDA approval · 2023-10-20
  FDA Approved: ROZLYTREK — Original Application (Genentech, Inc.)

  Rozlytrek (entrectinib) received FDA approval in an original application for the treatment of NTRK gene fusion-positive solid tumors and ROS…

• FDA approval · 2023-08-31
  FDA Approved: ROZLYTREK — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for Rozlytrek (entrectinib) submitted by Genentech, expanding its labeling.